Price$4.30-0.11 (-2.38%)
02:00 PM03:00 PM
News · 26 weeks46+129%
2025-12-072026-05-31
Mix2990d
- Insider12(41%)
- SEC Filings7(24%)
- Other6(21%)
- Earnings3(10%)
- Analyst1(3%)
Latest news
25 items- INSIDERDirector Mcnamara Robert was granted 22,214 shares, increasing direct ownership by 26% to 108,985 units (SEC Form 4)4 - AVITA Medical, Inc. (0001762303) (Issuer)
- INSIDERDirector Woody Joseph Fralin was granted 62,761 shares, increasing direct ownership by 314% to 82,761 units (SEC Form 4)4 - AVITA Medical, Inc. (0001762303) (Issuer)
- INSIDERDirector Tarnoff Michael E was granted 48,464 shares (SEC Form 4)4 - AVITA Medical, Inc. (0001762303) (Issuer)
- INSIDERDirector Cook Jeremy Curnock was granted 22,214 shares, increasing direct ownership by 56% to 62,050 units (SEC Form 4)4 - AVITA Medical, Inc. (0001762303) (Issuer)
- INSIDERDirector Crowe Suzanne was granted 22,214 shares, increasing direct ownership by 47% to 69,148 units (SEC Form 4)4 - AVITA Medical, Inc. (0001762303) (Issuer)
- INSIDERDirector Reed Jan Stern was granted 22,214 shares, increasing direct ownership by 44% to 73,225 units (SEC Form 4)4 - AVITA Medical, Inc. (0001762303) (Issuer)
- INSIDERDirector Woody Joseph Fralin bought $84,936 worth of shares (20,000 units at $4.25) (SEC Form 4)4 - AVITA Medical, Inc. (0001762303) (Issuer)
- INSIDERCFO O'Toole David D was granted 5,000 shares, increasing direct ownership by 3% to 150,927 units (SEC Form 4)4 - AVITA Medical, Inc. (0001762303) (Issuer)
- INSIDERPresident and CEO Vance Cary Guy was granted 5,000 shares, increasing direct ownership by 14% to 40,771 units (SEC Form 4)4 - AVITA Medical, Inc. (0001762303) (Issuer)
- INSIDERCFO O'Toole David D bought $8,520 worth of shares (2,000 units at $4.26), increasing direct ownership by 1% to 145,927 units (SEC Form 4)4 - AVITA Medical, Inc. (0001762303) (Issuer)
- INSIDERCFO O'Toole David D bought $8,480 worth of shares (2,000 units at $4.24), increasing direct ownership by 1% to 143,927 units (SEC Form 4)4 - AVITA Medical, Inc. (0001762303) (Issuer)
- PRAVITA Medical to Host Investor Webinar BriefingVALENCIA, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, President and Chief Executive Officer, and David O'Toole, Chief Financial Officer, on May 20, 2026, at 4:00 p.m. Pacific Time (May 21, 2026, at 9:00 a.m. Australian Eastern Standard Time). The webinar presentation will cover financial and business results from AVITA Medical's recent first quarter 2026 earnings webcast and will conclude with a Q&A session. Participants are invited to submit thei
- ANALYSTAvita Medical upgraded by Lake Street with a new price targetLake Street upgraded Avita Medical from Hold to Buy and set a new price target of $6.00
- SECSEC Form 10-Q filed by Avita Medical Inc.10-Q - AVITA Medical, Inc. (0001762303) (Filer)
- SECAvita Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AVITA Medical, Inc. (0001762303) (Filer)
- PRAVITA Medical Reports First Quarter 2026 Financial ResultsVALENCIA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions ("AVITA Medical," or the "Company"), today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights and Recent Business Updates Total revenue of approximately $19.3 million, up 4% year-over-year and approximately 10% sequentially, driven by contributions from Cohealyx® and improved RECELL® utilization as reimbursement dynamics normalizeAppointment of Cary Vance as President and Chief Executive Officer following a comprehensive search process led by a specia
- SECAvita Medical Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - AVITA Medical, Inc. (0001762303) (Filer)
- PRAVITA Medical Names Cary Vance as Chief Executive OfficerBoard appoints Cary Vance as President and Chief Executive Officer Follows successful interim tenure and thorough search process by the Board Jan Stern Reed elected as Chair of the AVITA Medical Board VALENCIA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company, today announced that its Board of Directors has appointed Cary Vance as President and Chief Executive Officer, effective immediately. The Board of Directors has also appointed Jan Stern Reed as its Chair, effective immediately. Mr. Vance, who has served as Interim CEO since October 2025, will continue to serve on the Board as an executive member.
- PRAVITA Medical Announces TGA Certification in Australia and Medsafe WAND Listing in New Zealand for RECELL GORECELL GO® receives regulatory clearance in Australia and New Zealand, enabling commercialization across both marketsRECELL GO is AVITA Medical's next-generation system that automates and standardizes the preparation of RECELL® Spray-On Skin™ for the treatment of burn and trauma wounds VALENCIA, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company delivering transformative solutions, today announced that RECELL GO, its next-generation system for preparing RECELL Spray-On Skin, has received certification from Australia's Therapeutic Goods Administration ("TGA") and has been listed on New Zealand's Web Assis
- PRAVITA Medical to Announce First Quarter 2026 Financial ResultsVALENCIA, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company, today announced that it will report its first quarter 2026 financial results after the close of the U.S. financial markets on Thursday, May 14, 2026. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, May 15, 2026, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights. First Quarter 2026 Webcast and Conference Call InformationTo listen to the conference call webcast, please register and join using the following link: https://edge.media-serve
- SECSEC Form DEF 14A filed by Avita Medical Inc.DEF 14A - AVITA Medical, Inc. (0001762303) (Filer)
- PRAVITA Medical Founder Fiona Wood Honored with Lifetime Achievement Award by American Burn AssociationRecognition highlights pioneering contributions to modern burn care including development of RECELL® Spray-On Skin™ VALENCIA, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company, today announced that its founder, Professor Fiona Wood, has been awarded the Lifetime Achievement Award by the American Burn Association (ABA). The award, the ABA's highest honor, recognizes individuals whose enduring contributions have advanced burn care, research, and education. Professor Wood was presented with the award during a ceremony at the ABA 2026 Annual Meeting. "Professor Wood not only has a remarkable legacy of achi
- PRAVITA Medical Announces Positive Interim Results from Cohealyx® Study Demonstrating Accelerated Time to Skin GraftingMean time to graft reduced to 13.6 days vs. 33.2 days real-world benchmark (~20 day reduction)Median time to graft of 11 days, with grafting as early as 5 daysStudy ongoing with full dataset expected in 2026Management to host Key Opinion Leader webinar at 4:30 p.m. ET on April 16 during the American Burn Association Annual Meeting VALENCIA, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ:RCEL, ASX: AVH)), a leading therapeutic acute wound care company, today announced positive interim results from its Cohealyx-I multi-center study demonstrating a reduction of nearly 20 days in mean time to skin grafting (13.6 days vs 33.2 days benchmark) for patients with full-thic
- SECSEC Form EFFECT filed by Avita Medical Inc.EFFECT - AVITA Medical, Inc. (0001762303) (Filer)
- SECSEC Form PRE 14A filed by Avita Medical Inc.PRE 14A - AVITA Medical, Inc. (0001762303) (Filer)
RCEL FAQ
6 questionsWhat does Avita Medical Inc. do?
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells...Where does RCEL stock trade?
Avita Medical Inc. (RCEL) is listed on NASDAQ.What sector and industry is RCEL in?
Avita Medical Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about RCEL?
Avita Medical Inc. has had 7 recent analyst actions on file. The most recent action was from Lake Street: Buy with a $600.00 price target on 2026-05-15.What companies are similar to RCEL?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare RCEL side-by-side with any of them on Quantisnow.How can I track RCEL on Quantisnow?
Quantisnow aggregates Avita Medical Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RCEL to receive live email and push alerts on every new disclosure.